62 results on '"Furumoto, Shozo"'
Search Results
2. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease
3. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease
4. Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand
5. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study
6. P-098 - Radiosynthesis and evaluation of [18F]SNFT-1 for imaging early tau deposition
7. Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain
8. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
9. Synthesis of [ 11C]interleukin 8 using a cell-free translation system and l-[ 11C]methionine
10. Evaluation of o-[ 11C]methyl- L-tyrosine and o-[ 18F]fluoromethyl- L-tyrosine as tumor imaging tracers by PET
11. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor
12. DEVELOPMENT OF A NOVEL 18F-LABELED PET TRACER FOR IMAGING ASTROGLIOSIS
13. DEVELOPMENT OF A NOVEL 18F-LABELED PET TRACER FOR IMAGING ASTROGLIOSIS
14. TO TAU OR TO MAO-B? MOST OF THE [F-18]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE
15. POTENTIAL APPLICATION OF 18F-THK5351 AND ITS DERIVATIVES FOR IMAGING ASTROGLIOSIS IN HUMAN BRAIN
16. POTENTIAL APPLICATION OF 18F-THK5351 AND ITS DERIVATIVES FOR IMAGING ASTROGLIOSIS IN HUMAN BRAIN
17. UTILITY OF 18F-THK5351 PET IN DIAGNOSIS AND DIFFERENTIATION OF NEURODEGENERATIVE DISEASES
18. SUCCESSFUL REDUCTION OF OFF-TARGET BINDING OF QUINOLINE DERIVATIVES AS TAU-SELECTIVE PET TRACERS
19. TAU PET IMAGING IN SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA USING 18F-THK5351 PET
20. NEUROFIBRILLARY TANGLE FORMATION AND SYNAPTIC LOSS: WHICH COMES FIRST?
21. IDENTIFICATION OF WAVELENGTH-DEPENDENT COMPOUNDS FOR IMAGING LEWY PATHOLOGY
22. [F-18]THK5351 RETENTION IS ASSOCIATED WITH THE PROGRESSION OF BRAIN ATROPHY IN PATIENTS WITH ALZHEIMER’S DISEASE
23. PATTERNS OF IN-VIVO PRECLINICAL TAU AND AMYLOID BURDEN USING [F-18]THK5351 AND [C-11]PIB
24. PATTERNS OF IN-VIVO PRECLINICAL TAU AND AMYLOID BURDEN USING [F-18]THK5351 AND [C-11]PIB
25. [F-18]THK5351 RETENTION IS ASSOCIATED WITH THE PROGRESSION OF BRAIN ATROPHY IN PATIENTS WITH ALZHEIMER’S DISEASE
26. Tau and amyloid imaging in presymptomatic and symptomatic Alzheimer’s disease with [F-18]THK5117 and [C-11]PiB: A multimodal imaging study
27. Validation of the binding specificity of Tau PET tracer [18F]THK-5351 on postmortem human brain samples
28. Distribution of tau pathology in the patients with mild cognitive impairment and Alzheimer’s disease measured with [18F]THK-5351 PET
29. Distribution of tau pathology in patients with mild cognitive impairment and Alzheimer’s disease measured with [18F]THK-5351 PET
30. Validation of the binding specificity of Tau PET tracer [18F]THK-5351 on postmortem human brain samples
31. BINDING CHARACTERIZATION OF TAU PET TRACER 18F-THK5117 IN NON-ALZHEIMER'S NEURODEGENERATIVE DISEASES
32. COMPARISON OF 18F-THK5117 AND 11C-PIB PET IMAGES IN PATIENTS WITH ALZHEIMER'S DISEASE
33. IN VIVO TAU IMAGING WITH 18F-THK5105 AND 18F-THK5117
34. ACCUMULATION OF THE NOVEL TAU IMAGING TRACER 18F-THK-5117 IS ASSOCIATED WITH BRAIN ATROPHY IN ALZHEIMER'S DISEASE
35. Binding characterization of novel PET tracer [18F]THK-5117 in the brains of people with Alzheimer's disease
36. In vivo detection of tau protein deposits in Alzheimer's disease using 18F-labeled 2-phenylquinoline derivatives
37. THK523 selectively binds to neurofibrillary tangles and neuropils in people with Alzheimer's disease
38. Detectable levels of white matter PHF-tau in Alzheimer's disease
39. In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy individuals from those with preclinical Alzheimer's disease
40. In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy controls from preclinical Alzheimer's disease
41. In vivo tau imaging in Alzheimer's disease and other dementias
42. Wavelength-dependent selective detection of tau pathology in Alzheimer's disease using a novel fluorescent probe THK-1188
43. Novel 18F-labeled quinoline derivatives for in vivo detection of tau pathology in Alzheimer's disease
44. In vivo tau imaging in Alzheimer's disease and other dementias
45. Phenylquinoline derivatives for in vivo imaging of tau pathology in Alzheimer's disease
46. Characteristics of the longitudinal cognitive profile and accumulation of amyloid-beta protein in Alzheimer's disease patients with or without diabetes mellitus
47. Near-infrared fluorescence probe X50 for in vivo detection of amyloid plaques in the brain
48. PET imaging with BF-227 in dementia with Lewy bodies
49. Binding and pharmacokinetic properties of novel 18F-labeled agents for in vivo imaging of tau pathology in Alzheimer's disease
50. Characterisation of [18F]-THK523, a novel in vivo tau imaging ligand
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.